Durvalumab plus tarlatamab cuts death risk 58% in extensive‑stage small cell lung cancer Phase III trial
A Phase III trial of the combination of AstraZeneca’s durvalumab and Amgen’s bispecific antibody tarlatamab showed a 58% relative reduction in death risk versus durvalumab alone in extensive‑stage small cell lung cancer. Median overall survival increased to 21.1 months from 12.7 months. The study enrolled 563 patients across 29 countries and will lead Amgen to file regulatory submissions for the earlier‑line use of tarlatamab.
Why it matters
The results could expand tarlatamab’s label to earlier‑line treatment, creating a new revenue stream for Amgen and a co‑marketing opportunity for AstraZeneca. Investors should watch for upcoming regulatory filings and potential commercial launch timelines.
Key facts
- 1The combination reduced the relative risk of death by 58% compared with durvalumab alone. tradingview.com
- 2Median overall survival was 21.1 months for the combination versus 12.7 months for durvalumab alone. tradingview.com
- 3The trial enrolled 563 patients treated at 175 medical centers in 29 countries. ynetnews.com
- 4Severe or life‑threatening adverse events occurred in 46.8% of patients receiving the combination versus 40.6% in the control group. ynetnews.com
- 5Amgen plans regulatory submissions for the earlier‑line use of tarlatamab. ynetnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.